Sirolimus-induced regression of a large orbital lymphangioma.

Lagrèze, Wolf A; Joachimsen, Lutz; Gross, Nikolai; Taschner, Christian; Rössler, Jochen Karl (2019). Sirolimus-induced regression of a large orbital lymphangioma. Orbit, 38(1), pp. 79-80. Taylor & Francis 10.1080/01676830.2018.1436569

Full text not available from this repository. (Request a copy)

Microcystic lymphatic malformations are difficult to treat surgically, especially when located in the orbital apex. Recently, pharmacologic inhibition of the mTOR pathway by sirolimus was reported as a safe and efficacious treatment option for lymphatic malformations (also known as lymphangiomas). We report the case of a young male patient in which a unilateral, retrobulbar lymphatic malformation regressed to a large extent under treatment with 1 mg sirolimus given orally twice a day over a period of six months.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine

UniBE Contributor:

Rössler, Jochen Karl

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1744-5108

Publisher:

Taylor & Francis

Language:

English

Submitter:

Karen Lidzba

Date Deposited:

26 Feb 2019 08:39

Last Modified:

12 Apr 2019 01:31

Publisher DOI:

10.1080/01676830.2018.1436569

PubMed ID:

29405800

Uncontrolled Keywords:

Lymphangioma lymphatic malformation mTOR orbit sirolimus

URI:

https://boris.unibe.ch/id/eprint/124289

Actions (login required)

Edit item Edit item
Provide Feedback